Since 2015, China’s regulatory agencies have introduced a number of reforms, leading to faster review timelines and easier market access. As the pandemic spread around the globe, with extended waves in the US and Western Europe, a trend emerged to conduct clinical trials outside these areas in order to keep trial timelines on track. Between January 2018 and January 2021, China saw a 163% increase in recruiting trial sites. By 2024, China is expected to be the second largest market for clinical trials behind the US.
Including China in your global development plans presents many long-term strategic opportunities. In this webinar, we will introduce you to the current regulatory requirements in China. Additionally, we will discuss recent case studies on potential regulatory pathways leading to new imported and local drug registration in China, including information on the IND and NDA process and timeline. dMed-Clinipace look forward to your participation!